Organovo
Biotechnology company developing three-dimensional bioprinted human tissues for drug discovery, toxicology, disease modeling, and potential therapeutic applications.
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Organovo is a San Diego biotechnology and medical research company focused on three-dimensional bioprinting of functional human tissues. The company was established in 2007 and built its business around the idea that living, human-cell-based tissue models could make preclinical research more predictive than conventional two-dimensional cell cultures and could help reduce reliance on animal testing in selected applications. Organovo's technology uses cells and supportive biomaterials to construct tissue structures layer by layer. The company's internally developed NovoGen MMX Bioprinter was designed to deposit cellular material in controlled patterns, allowing researchers to produce engineered tissues with selected structural and biological characteristics. In a typical workflow, cells may be isolated from a biopsy or other biological source, expanded in culture, combined with a material that supports their survival, and assembled into a three-dimensional tissue model. The resulting tissue can then be used outside the body for laboratory testing. The company's principal commercial focus has been pharmaceutical and medical research rather than routine clinical transplantation. Organovo has developed and marketed tissue models intended for drug discovery, preclinical safety testing, toxicology, and disease research. Its ExVive3D portfolio has included liver and kidney tissue models. These products are intended to give researchers a more physiologically relevant environment in which to examine drug response, tissue injury, and disease mechanisms before moving a candidate into human trials. The strategic promise is to improve the quality of early decisions, potentially shorten development timelines, and identify harmful or ineffective compounds earlier. Organovo has also pursued collaborations with pharmaceutical companies, academic medical centers, and other life-science organizations. These relationships have been used to design, produce, and validate specialized tissues for particular research questions. In 2015, the company entered an agreement with L'Oréal to provide processes and technology for producing three-dimensionally printed human skin for cosmetic-product safety and efficacy testing. This collaboration illustrated an application beyond pharmaceutical development and positioned bioprinted tissue as an alternative or supplement to conventional testing models. The company's longer-term vision has included therapeutic uses such as surgical repair and transplantation. Such applications require substantially greater evidence, manufacturing control, regulatory validation, vascularization, durability, and clinical safety than laboratory tissue models. Consequently, Organovo's established business has centered on research-use tissues and related technology rather than approved replacement organs. Organovo became a publicly traded company through a 2012 reverse merger with Real Estate Restoration and Rental, Inc., initially accessing OTC markets. In July 2013, it uplisted to the NYSE MKT. Its public-market history reflects the speculative nature of early-stage biotechnology and the substantial gap between demonstrating a promising platform and creating a large commercial medical business. The company has continued to operate under the ONVO ticker, with its activities focused on engineered human tissues and related discovery programs. In February 2025, Eli Lilly acquired Organovo's FXR program for $10 million, providing a notable example of the company monetizing a research asset outside its core tissue-modeling activities.
History
Organovo was established in 2007 with a focus on using three-dimensional bioprinting to create functional human tissues. Its founding concept was that engineered tissues made from human cells could provide researchers with more informative experimental systems than flat cell cultures. The company was associated with Gabor Forgacs and developed an internal platform known as the NovoGen MMX Bioprinter. The bioprinting process is based on arranging living cells and supportive materials into controlled three-dimensional structures. Depending on the application, cells can be obtained from a biological sample, expanded outside the body, combined with a medium or biomaterial that helps sustain them, and deposited in a programmed pattern. The resulting tissue is intended to reproduce selected features of human biology, although it is not equivalent to a complete human organ and does not automatically qualify for clinical use. Organovo's commercial and research strategy concentrated first on laboratory applications. The company developed tissue models for pharmaceutical research, including models intended to support drug discovery, toxicology, and disease modeling. Its ExVive3D products included liver and kidney tissue models. These models were designed to help researchers study how compounds affect human tissues before candidates progress into clinical testing. The approach sought to improve preclinical decision-making, reduce avoidable development costs, and potentially limit the need for some animal experiments. The company also worked with biopharmaceutical organizations and academic medical centers to create and validate tissues tailored to particular research questions. A 2015 agreement with L'Oréal extended the platform into cosmetics, with Organovo supplying processes and technology for three-dimensionally printed human skin to support the testing of cosmetic products. This collaboration demonstrated the broader potential of engineered tissues as testing tools, while also showing that the near-term commercial opportunity was in research services and laboratory models rather than transplantable organs. Organovo became publicly traded in 2012 through a reverse merger with Real Estate Restoration and Rental, Inc., a shell company, and initially traded on OTC markets. In July 2013, it uplisted to the NYSE MKT. The company attracted significant public-market attention during the early 3D-bioprinting investment cycle; the reference material records a market-capitalization high of approximately $700 million in 2013. It also records a rise in shares outstanding from 22.4 million at the time of listing to more than 130 million by 2020. These figures reflect the capital-market history of the public company but do not by themselves establish commercial success or profitability. Organovo's longer-term research ambitions included therapeutic applications, such as surgical repair and transplantation. Those goals face demanding scientific and regulatory barriers, including the creation of durable, vascularized, functional tissues and the demonstration of safety and efficacy in clinical settings. The company's more established role has therefore remained connected to preclinical research and engineered tissue models. In February 2025, Eli Lilly purchased Organovo's FXR program for $10 million. The transaction marked a later-stage asset monetization event and showed that Organovo's research portfolio extended beyond tissue-model products. Organovo remains identified with 3D bioprinting and human tissue engineering, while its public-company history illustrates the uncertainty and long development timelines typical of platform biotechnology businesses.
- 2025
FXR program sold to Eli Lilly
[1]Eli Lilly purchases Organovo's FXR program for $10 million in February, creating a transaction around a defined research asset.
- 2015
L'Oréal skin-printing agreement
[1]Organovo signs an agreement to provide processes and technology for producing 3D-printed human skin for L'Oréal's cosmetic-product testing activities.
- 2013
Uplisting to NYSE MKT
[1]Organovo uplists from the OTC markets to the NYSE MKT in July, increasing its visibility among public-market investors.
- 2012
Public-market entry through reverse merger
[1]Organovo becomes publicly traded through a reverse merger with Real Estate Restoration and Rental, Inc., initially accessing OTC markets.
- 2007
Organovo is established
[1]Organovo is established as a biotechnology company focused on three-dimensional bioprinting and functional human tissue development.
Products and positioning
Human-relevant 3D bioprinting and engineered tissue models for drug discovery, toxicology, disease modeling, and translational research.
3D bioprinted tissue model
ExVive3D liver model
A laboratory liver-tissue model produced through Organovo's bioprinting platform. It is intended for pharmaceutical research, including investigation of drug response, toxicity, and disease-related processes. The model is positioned as a human-relevant in vitro system that can complement conventional cell cultures and other preclinical methods.
3D bioprinted tissue model
ExVive3D kidney model
A three-dimensional kidney tissue model developed for laboratory research and preclinical investigation. Its intended uses include studying tissue behavior, compound effects, and toxicity in a structured human-cell-based environment. It is a research model rather than an approved replacement kidney or transplant product.
Bioprinting technology
NovoGen MMX Bioprinter
Organovo's internally developed bioprinting system for arranging living cellular material into three-dimensional tissue structures. The platform supports the company's tissue-model development and research collaborations, although the printer itself is best understood as enabling technology rather than a consumer product.
Engineered tissue technology · 2015
3D-printed human skin technology
Processes and technology supplied for producing three-dimensionally printed human skin for laboratory testing. In 2015, Organovo agreed to provide this capability to L'Oréal for evaluating the safety and efficacy of cosmetic products.
Marketing campaigns
- 2015L'Oréal 3D-printed skin collaboration
International cosmetics research · Europe · United States
Organovo partnered with L'Oréal to provide processes and technology for producing 3D-printed human skin. The collaboration promoted the use of engineered tissue as a laboratory tool for cosmetic-product safety and efficacy testing.
Outcome. The agreement broadened the visible application range of Organovo's platform beyond pharmaceutical drug discovery, although the available reference does not provide detailed commercial or technical results.
Brand decisions
2025
Sell the FXR program to Eli LillyM&ABackground
Organovo held an FXR research program alongside its core focus on bioprinted tissue models and medical research applications.
Action taken
Eli Lilly purchased the FXR program from Organovo for $10 million in February 2025.
Aftermath
The transaction monetized a defined research asset and transferred the program to a major pharmaceutical company. The available reference does not specify the program's subsequent development plans.
Purchase price. $10 million (February 2025)
2013
Uplist to NYSE MKTStrategyBackground
After entering public markets through OTC trading, Organovo pursued a more prominent exchange listing as investor interest in bioprinting and biotechnology grew.
Action taken
Organovo uplisted to the NYSE MKT in July 2013.
Aftermath
The listing increased the company's public-market profile. Reference material also records a 2013 market-capitalization high of approximately $700 million, without establishing that this valuation was sustained.
Approximate market capitalization. $700 million high (2013)
2012
Enter public markets through a reverse mergerStrategyBackground
Organovo sought public-market access while developing an early-stage biotechnology platform centered on 3D-bioprinted human tissues.
Action taken
The company completed a reverse merger with Real Estate Restoration and Rental, Inc. and began trading on OTC markets.
Aftermath
The transaction established Organovo as a public company and was followed by an uplisting to the NYSE MKT in 2013.
Recent events
LifeNet Health acquires Samsara Sciences assets[3]
Reported:
LifeNet Health paid $1.5 million for the assets of Samsara Sciences, an Organovo subsidiary that provides human liver cells for drug research.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/organovo · Editorial policy · How profiles are compiled